Monument Capital Management Purchases 2,042 Shares of Johnson & Johnson (NYSE:JNJ)

Monument Capital Management raised its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 96.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,165 shares of the company's stock after purchasing an additional 2,042 shares during the quarter. Monument Capital Management's holdings in Johnson & Johnson were worth $691,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after buying an additional 1,772,706 shares in the last quarter. Geode Capital Management LLC boosted its stake in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after buying an additional 1,561,036 shares in the last quarter. Northern Trust Corp grew its position in Johnson & Johnson by 12.3% during the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after acquiring an additional 3,363,235 shares during the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $4,390,037,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Johnson & Johnson by 1.8% in the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after acquiring an additional 431,205 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Barclays dropped their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Trading Up 0.2%

Shares of Johnson & Johnson stock traded up $0.34 during midday trading on Thursday, reaching $155.90. 3,482,521 shares of the company's stock traded hands, compared to its average volume of 8,047,072. The stock has a 50 day moving average of $153.63 and a 200-day moving average of $153.88. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a market cap of $375.11 billion, a PE ratio of 17.34, a price-to-earnings-growth ratio of 2.35 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.34%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.